Article by Growth Op
Francis Collins, the director of the National Institutes of Health (NIH), praised the potential of psychedelic research during a Senate budget hearing last week.
“As we’ve learned more about how the brain works, we’ve begun to realize that these are potential tools for research purposes and might be clinically beneficial,” Collins said, per Benzinga. Collins also admitted there are far too many barriers interfering with cannabis research.
Collins highlighted the resurgence in psychedelic research, particularly around psilocybin, which has been through three clinical trials for depression in the U.S.
“That could be quite exciting, because we all are looking for new approaches to that,” he said, adding that MDMA and LSD are also of interest.
On the topic of cannabis and greater access to the plant for researchers, Collins said “We’re making some progress.”